News coverage about Eleven Biotherapeutics (NASDAQ:EBIO) has been trending positive on Saturday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eleven Biotherapeutics earned a daily sentiment score of 0.26 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.5708133313414 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Should Farsighted Investors Pay Attention to Eleven Biotherapeutics, Inc. (NASDAQ:EBIO)? – FLBC News (flbcnews.com)
- Eleven Biotherapeutics, Inc. (EBIO) has a value of $1.12 per share While Quotient Limited (QTNT) is stand at $3.91 – Stocks Gallery (stocksgallery.com)
- Stock Moving Towards 52-Week Low Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) – Sparta Review (spartareview.com)
- Bargain Hunter’s Delight: What’s the Latest on Eleven Biotherapeutics, Inc. (NASDAQ:EBIO)? – FLBC News (flbcnews.com)
- Tracking Trends in Biotechnology (kait8.com)
Shares of Eleven Biotherapeutics (NASDAQ EBIO) traded down 0.89% during trading on Friday, reaching $1.11. 490,916 shares of the company’s stock were exchanged. The stock has a market cap of $17.09 million, a P/E ratio of 10.18 and a beta of 3.31. Eleven Biotherapeutics has a 12-month low of $1.00 and a 12-month high of $5.40. The company has a 50 day moving average of $1.46 and a 200 day moving average of $1.74.
EBIO has been the topic of several analyst reports. Zacks Investment Research upgraded shares of Eleven Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 16th. ValuEngine downgraded shares of Eleven Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, June 13th.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/08/19/eleven-biotherapeutics-nasdaqebio-getting-favorable-news-coverage-report-shows-updated.html.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
What are top analysts saying about Eleven Biotherapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eleven Biotherapeutics Inc. and related companies.